————————2022 Healthy China Innovative Practice Case Collection and Display Activity————————

On December 28, the Second People's Health Conference and the 2022 Healthy China Innovative Practice Case Collection Summary Conference were held in Beijing. Organized by People.cn - People's Health, the conference received academic support from the Chinese Preventive Medicine Association, Chinese Health Education Center, National Center for Mental Health, China, Coordination and Promotion Office of the Healthy China Enterprise Action of China Enterprise Confederation, and the China Institute of Sport Science. On the conference, representatives gathered to share innovative experiences and successes since the implementation of the Healthy China Initiative, contributing ideas and strategies to promote the construction of a healthy China. The conference announced the "2022 Healthy China Innovative Practice Cases", and the "Intelligent Clinical Research Platform Facilitating Clinical Studies" submitted by Elixir Clinical Research was selected as an innovative practice case in the category of "Innovative Potential".

At the conference, Qun'an Mao, Deputy Director of the Office of the Healthy China Initiative Promotion Committee, Deputy Director of the National Patriotic Health Campaign Committee, and Director of the Planning Department of the National Health Commission, delivered a speech. 

Lingli Zhang, Deputy Secretary-General of the Chinese Preventive Medicine Association, presented and commented on typical cases of Healthy China innovative practices.

To deeply implement the "Healthy China Initiative (2019-2030)", continuously explore and promote practical cases of the Healthy China Initiative, as well as fully promote the construction of a healthy China, the collection activity for typical cases of 2022 Healthy China Innovative Practice, under the guidance of the Office of the Healthy China Initiative Promotion Committee, was launched in May this year. After two rounds of review by experts from academic support units, typical cases of four categories – "Local Practice," "Health Responsibility," "Diverse Integration," and "Innovative Potential" – were selected.

Those who recognize the trend are wise, and those who ride the trend will win. Implementing the Healthy China Initiative and improving the national health level is the focus of societal attention. As a technology-driven, full-service clinical CRO in the era of artificial intelligence, Elixir Clinical Research is dedicated to accelerating new drug development and contributing to the construction of a "Healthy China".

It typically takes decades for a new drug from the beginning of its development to market approval, which involves substantial costs and often requires investment of hundreds of millions, with nearly 90% of the drugs being eliminated during the stage of phase I clinical trials. High investment, high risk, and long cycles of new drug development are pressing challenges that need to be addressed.

The intervention of artificial intelligence offers new breakthroughs in the marathon-like drug development process. Elixir Clinical Research has developed an intelligent clinical research platform based on big data and AI technologies. Starting from actual needs of the patients, integrating digital technology and innovative services, the platform connects and empowers all parties involved in clinical trials. It helps to accelerate the research and marketing processes of new drugs, shorten the development cycle of new drugs, reduce the cost of drug development, and increase the success rate of new drug development.

Driven by digital intelligence and through standardized data collection, data from different systems or sources can be collected into the intelligent clinical research platform in unified format and transmission mode. The platform automatically verifies the consistency between source and target data. After verification, the target data undergoes data cleansing, mainly focusing on classification, format conversion, and validation needed for research projects. After data cleansing, data governance is conducted, involving data mapping transformation, terminology set mapping, and Unicode transformation according to CDISC data structure. The data is then displayed on the intelligent clinical research platform, configured with statistical models to present statistical results.

The intelligent clinical research platform support system not only enables rapid retrieval and browsing of historical medical records, but also conveniently applies clinical data to specific research, becoming an efficient tool for hospitals' departments and pharmaceutical companies to conduct clinical research. It accelerates academic research and promotes the transformation of achievements, unlocking the potential academic value of medical data.

At the hospital level, on both the clinical research big data platform and application platform, Elixir Clinical Research has achieved the integration and governance of historical and real-time data from various business systems. The governed data ensures the quality of clinical research data. Based on this, clinical research staff from various departments can access data more conveniently and manage research more efficiently, thus enhancing the overall research efficiency, continuously improving academic research capabilities, and elevating both the quality and quantity of the hospital's clinical academic research.

In the pharmaceutical field, where R&D innovation directly impacts people's life and health, Elixir Clinical Research continually contemplates how pharmaceutical innovation can shoulder the responsibility of promoting industry development and meeting clinical needs. Against the backdrop of national health consciousness, the post-pandemic shift in medical paradigms, and the health service demands of people in the new era, Elixir Clinical Research will continue to provide new pathways for pharmaceutical innovation with its solid R&D strength and exceptional technological capabilities to safeguard patients' health.

For more details, please contact 

info@ecr-global.com